RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $218 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $218 price target.
June 06, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital's Brian Abrahams reiterated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a $218 price target.
The reiteration of the Outperform rating and maintenance of the $218 price target by RBC Capital's analyst indicates a positive outlook for Sarepta Therapeutics. This news is likely to have a positive short-term impact on the stock price, as it shows confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100